| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 401.35% | £350,947.87 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 317.99% | £292,591.69 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 221.00% | £224,702.12 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 54.10% | £107,867.39 |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | 50.45% | £105,317.22 | |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 43.02% | £100,114.84 |
| Lord Mance |
|
Stryker / NYQ:SYK | 26.56% | £88,592.00 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 3.16% | £72,210.53 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -2.95% | £67,935.12 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -14.94% | £59,538.55 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -36.65% | £44,342.28 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |